Anbio Biotechnology (NASDAQ: NNNN) has a price-to-earnings ratio that is above its average at 597.36x.
The public float for NNNN is 39.69M, and at present, short sellers hold a 0.11% of that float. On July 03, 2025, the average trading volume of NNNN was 83.62K shares.
NNNN) stock’s latest price update
The stock of Anbio Biotechnology (NASDAQ: NNNN) has increased by 15.14% when compared to last closing price of $31.44. Despite this, the company has experienced a 13.73% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-15 that Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration
NNNN’s Market Performance
NNNN’s stock has risen by 13.73% in the past week, with a monthly rise of 357.36% and a quarterly rise of 397.94%. The volatility ratio for the week is 15.14% while the volatility levels for the last 30 days are 16.97% for Anbio Biotechnology The simple moving average for the past 20 days is 104.47% for NNNN’s stock, with a 292.02% simple moving average for the past 200 days.
NNNN Trading at 219.19% from the 50-Day Moving Average
After a stumble in the market that brought NNNN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.36% of loss for the given period.
Stock Fundamentals for NNNN
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.72 for the gross margin
The net margin for Anbio Biotechnology stands at 0.29. The total capital return value is set at 0.13. Equity return is now at value 15.00, with 13.83 for asset returns.
Currently, EBITDA for the company is 2.57 million with net debt to EBITDA at -4.59. When we switch over and look at the enterprise to sales, we see a ratio of 178.19. The receivables turnover for the company is 8.31for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.71.
Conclusion
To sum up, Anbio Biotechnology (NNNN) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
